Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-555: Subcutaneous vs Intravenous Pembrolizumab in Advanced Melanoma
NCT03665597Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2018
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in melanoma (7 cohorts), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve of Pembrolizumab, Maximum Plasma Concentration of Pembrolizumab and 2 more. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03665597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665597.